Aspira Women's Health Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mike Buhle

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	1.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Mike Buhle

less than a year

Mandato

Mr. Michael Buhle, also known as Mike, is the Chief Executive Officer of Aspira Women's Health Inc.since January 28 2025 and its Chief Commercial Officer since January 28, 2025. Mr. Buhle has experience dr...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sandra Milligan	President	less than a year	US$447.98k	0.082% $ 3.8k
Michael Buhle	CEO & Chief Commercial Officer	less than a year	Nessun dato	Nessun dato
James Crawford	VP of Finance & Principal Accounting Officer	less than a year	Nessun dato	Nessun dato
Nicolette Possemato	Senior Vice President of Human Resources	2.9yrs	Nessun dato	Nessun dato
Michelle Snider	Senior Vice President of Commercial Strategy & Operations	1.5yrs	Nessun dato	Nessun dato
Jamie Sullivan	Chief of Staff & ARPA-H Program Director	no data	Nessun dato	Nessun dato

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di AWH non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
John Ragard	Independent Director	less than a year	US$25.54k	0.75% $ 34.9k
Ellen Vos	Independent Director	1.8yrs	US$60.28k	0.35% $ 16.2k
Jannie Herchuk	Independent Chair of the Board	1.8yrs	US$80.89k	0.34% $ 16.0k
Stefanie Cavanaugh	Independent Director	1.8yrs	US$63.16k	0.37% $ 17.0k
Winfred Parnell	Independent Director	1.7yrs	US$58.72k	0.37% $ 17.0k
Donald Munroe	Member of Scientific Advisory Board	no data	US$484.75k	Nessun dato
Farr Nezhat	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Celeste Fralick	Independent Director	3yrs	US$57.58k	0.30% $ 14.2k
Leo Twiggs	Chairman of Clinical Advisory Board	1.3yrs	Nessun dato	Nessun dato
Levi Downs	Member of Clinical Advisory Board	1.3yrs	Nessun dato	Nessun dato
Nisha Garg	Member of Clinical Advisory Board	1.3yrs	Nessun dato	Nessun dato
Tamika Sea	Member of Clinical Advisory Board	1.3yrs	Nessun dato	Nessun dato

1.5yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di AWH non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/02/12 08:15
Prezzo dell'azione a fine giornata	2025/02/12 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Aspira Women's Health Inc. è coperta da 10 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners
Benjamin Haynor	Alliance Global Partners
Laura McGuigan	B. Riley Securities, Inc.

Aspira Women's Health Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Aspira Women's Health Inc. Announces Board Changes

Aspira Women's Health Inc. Appoints James Crawford as Principal Accounting Officer

Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations

Aspira Women's Health Announces Resignation of John Kallassy as Interim Chief Financial Officer, Effective January 10, 2025

Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

Recent updates

Aspira Women's Health Inc. Announces Board Changes

Aspira Women's Health Inc. Appoints James Crawford as Principal Accounting Officer

Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations

Aspira Women's Health Inc. has filed a Follow-on Equity Offering.

Aspira Women's Health Announces Resignation of John Kallassy as Interim Chief Financial Officer, Effective January 10, 2025

Aspira Women's Health Inc. Provides Nasdaq MVLS Non-Compliance Update

Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member

Aspira Women's Health Inc. Successfully Reaches the First Milestone of the Advanced Research Projects Agency for Health $10 Million Award

Aspira Women's Health Inc. announced delayed 10-Q filing

Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024

Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health

Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

New major risk - Shareholder dilution

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million.

Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

New major risk - Shareholder dilution

Aspira Women's Health Inc. announced that it has received $1.910249 million in funding

Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024

Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Price target decreased by 41% to US$3.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024

Price target increased by 24% to US$5.60

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million.

Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors

Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Consensus revenue estimates decrease by 13%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023

High number of new directors

Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Aspira Women's Health Establishes A New Clinical Advisory Board

Aspira Women’s Health Regains Nasdaq Compliance

Aspira Women’s Health Announces Executive Changes

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Consensus EPS estimates upgraded to US$2.13 loss, revenue downgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors

High number of new and inexperienced directors

Consensus revenue estimates decrease by 13%

Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023

First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022)

Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors

Full year 2022 earnings: EPS exceeds analyst expectations

Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Receives A Written Notice from Nasdaq

Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind